cancer

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023”
Oh, 48 weeks! !

there could be a cure/preventative for breast cancer out there

They have a great product treating cancer with immunotherapy, peer reviewed journal

Alzheimer therapies are on the top of choices.

A drug that actually helps without any major side effects  .. and breakthrough therapy. .

$AVXL The oral Anavex 2-73 therapy met the primary and secondary endpoints of the trial, with patients receiving the therapy experiencing statistically significant improvement in cognition.

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

drug

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

patient

It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

Hepion Pharmaceuticals Inc

hand

10% of the float is in institutional index funds hands and that is shite.

In the last 2 years many weak hands have lost money selling for desperation..We are all  Screwed since we were part of a well organized fraudulent plan.

Won’t give them another dollar from my hand earned money…

Where you  perhaps you planned to spend what time you have might , if you are caught , just slip out of your hands !

short

The naked shorters are starting to feel the cactus being slowly shoved up their asses.

$HEPA $CVNA Shorts in big trouble in both these tickers

$HEPA shorties better cover!! 🤦🏼‍♂️🤦🏼‍♂️🤡🤡😂😂😂

$HEPA it seems like shorts got caught naked.

Sit there bitching and complaining about shorts.

Shorts are trapped and face more issues as share prices continues rising.

shit

$HEPA Can someone please explain to me why longs keep torturing themselves day after day by holding on to this crap?

$HEPA MMs using six decimals is effing bullshit!

In addition to NASH,  Rencofilstat appears to be effective against Multiple Myeloma and Prostate Cancer.

but the Liver Cancer (HCC) indication and ability to treat alcohol liver disease alone make Rencofilstat a potential top tier therapeutic - on top of NASH.

This makes Rencofilstat a promising candidate for the treatment of a variety of diseases, including thromboembolic disorders, sepsis, and cancer.

This cancer stuff is very promising indeed, 

It is regarded as an incredible drug that almost cures cancer.

“killed 70% – 90% of the cancer cells (4 different cell lines) over two days.

news

$HEPA the consolidation over last weeks is bullish … one day it will explode above 0,88$ or maybe with Gap Up after news … the day is near , Szenario destroyed &lt; 0,66$

The news for $NVS and $PLRX closing their relationship in NASh is good for $HEPA, in my opinion.

prepare for the positive news they know is coming.

The good news is that this stock can be manipulated both ways.

$HEPA 20 something percent haircut over a great news.

$HEPA @BioTuesdays good to see bioTuesday has so much great HEPA news to put out that they have to release some of it on Wednesday ! 🤣

The only thing im sure about with this company is that its drug has great potential

if this is truly a 4B, 5B or more mkt cap drug it’ll ultimately end up with a SP in the hundreds of dollars (assuming RS goes through) and everyone will be happy in the long run.

Despite everything, the fact remains that absolutely nobody has come up with anything substantially bad to report about this amazing drug.

For any investor, being able to buy the company below cash value while getting the wonder drug, Rencofilstat, for free is a VERY attractive investment proposition.

That drug has been proven to be safe to be used in tandem with any other known drugs.

$HEPA this drug is game changer in hepatology!

2023 is going to be highlighted with a continuous cascade of amazingly positive PR’s confirming the fact (already documented in 300+ early clinical studies), that Rencofilstat is truly a Wonder Drug to be celebrated, with an extraordinarily large TAM.

My recommendation is to trust the science and say Buy! Buy!

$HEPA Big nice buy orders being executed. @.

$HEPA this is an extreme buy and HOLD- no one should be selling a share

$HEPA Hold enjoy the ride 3+ million volume, there is something BIG going on..with the Implied VOlatality fluctuation and premium on options.

$HEPA Great pop in pre-market, has some good strength coming back after a big sell.

but that’s good for bios lately so after a morning dip $LABU goes higher taking us with it🤷 
go big blue!

Its definitely leaning towards a big run coming soon.

The volume today is going to activate alarm bells up &amp; down Wall Street and attract a lot of big money looking for a solid biotech investment. 🎉

$HEPA next leg up coming imo.. big news for a multi day run 🗞️

BIG props to our team of scientists, clinicians and entire team!! !

I can&#39;t stress enough how big a deal this is.

$HEPA deff see us making big $$$ at some point

TG Therapeutics Inc

trading

Unbelievable how negative this stock trades against bio stocks with not much going on besides mediocre trials.

Big Loser Alert: Trading today&#39;s -7.2% move in TG THERAPEUTICS $TGTX https://wp.me/p5bLGB-iva5

↳ Why are you paying to be in a Trading Room?

action

$TGTX stock action negative this whole week.

$TGTX we&#39;re missing something here, the price action is a bit worrisome.

This price action is pathetic after holding this bag for years.

life

manipulation

It&#39;s eye opening to see the blatant manipulation.

$TGTX no real sellers here, all fake manipulation

Screw off $GS   hope they get crushed from the sec for stock manipulation  I can’t stand these fools.

Practically the only thing red today… lame 😒

$TGTX $19.00 in the red 😎 this thing sends chills down my arms.

$TGTX
MOST CONVENIENT- 50% faster infusion
  
SAFEST - Zero Breast Cancer Risk

MOST AFFORDABLE - By far

If TGTX was a Big Pharma Company, the medical press would be blowing it up with praise.

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

- Lowest ARR rate, no black box label, reduced brain lesions, and no reports of breast cancer.

Lowest ARR rate, no black box warning label, reduced brain lesions, and no reports of breast cancer (there are reports of breast cancer with other MS treatments, and 75% of people with MS are women).

$TGTX &quot;4 Stories of Living with Multiple Sclerosis&quot; 
Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.

Major upgrade for patients and infusion centers

-No major health threats like breast cancer or sever liver damage like main competition

$TGTX possibly the best therapy available for MS patients that exists today!

MS is 3 times more common in women and there were no reports of breast cancer compared to the competition!

hold

$TGTX Worthwhile hold and in time will be quite profitable.

$TGTX Please hold your shares or buy more on the dip You will be very pleased with the outcome

$TGTX good day Bulls, just hold for the gold!! !

This will be huge, and the sp for BO will be massive in 2yrs if they hold out. 100+

Buy, Accumulate, Hold…it’s common sense.

$TGTX &gt; STRONG BUY = BUY/HOLD/ACCUMULATE.

market

Chartwise,  i  would think  this  is   pretty bullish;  given  crap  market. Thoughts?

$TGTX This is the rocky Biden market u all wanted.

Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.

$TGTX market is doing good, we doing good

$TGTX Looking strong today despite the market.

TG&#39;s Briumvi is positioned to take market share because of these advantages, including how much better it is than all other competitors.

$TGTX  
I found this on NewsBreak: The stock market is on the verge of a rare bullish trifecta that suggests big upside ahead  
https://share.newsbreak.com/2tuqqt3a

I have done plenty of research lately on the market TAM and this looks primed to move quickly once it gets rolling.

$TGTX Up 23% from the lows of pre market 3 trading days ago.

The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”

In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.

ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.

beyond TG doing well, and us all making a ton of profit, i genuinely hope that this is the answer a lot of MS patients need to help them navigate &amp; improve their illness.

Getting the best available treatment for the lowest price is a no brainer.

We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey.

They&#39;re FDA approved, have the best in class treatment, and is more affordable than the others.

Top Stocks matching your search for "shares cancer"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.